Literature DB >> 12372437

Inhibition of Candida albicans secreted aspartic protease by a novel series of peptidomimetics, also active on the HIV-1 protease.

Damiano Skrbec1, Domenico Romeo.   

Abstract

Nineteen reduced amide, monohydroxy- or dihydroxyethylene-based transition-state peptidomimetics, known to be good inhibitors of the aspartic protease of HIV-1, were tested against a secreted aspartic protease (Sap2), purified from the culture medium of a virulent strain of Candida albicans. Ten of these compounds exhibited IC(50)s against Sap2 lower than 15 microM; the best inhibitor, Kyn-Val-Phe-Psi[OH-OH]-Phe-Val-Kyn, when added to the C. albicans culture, repressed the hydrolysis of bovine serum albumin (BSA), contained in the culture medium, and inhibited the growth of the fungus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372437     DOI: 10.1016/s0006-291x(02)02372-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Tetracycline-inducible expression of individual secreted aspartic proteases in Candida albicans allows isoenzyme-specific inhibitor screening.

Authors:  Peter Staib; Ulrich Lermann; Julia Blass-Warmuth; Björn Degel; Reinhard Würzner; Michel Monod; Tanja Schirmeister; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

2.  HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites.

Authors:  Rhian E White; David J Powell; Colin Berry
Journal:  FASEB J       Date:  2011-01-25       Impact factor: 5.191

3.  Virulence factors and genetic variability of vaginal Candida albicans isolates from HIV-infected women in the post-highly active antiretroviral era.

Authors:  Pâmela Cristina Mastellaro Delvas Zanni; Patrícia de Souza Bonfim-Mendonça; Melyssa Negri; Sandra Sayuri Nakamura; Lucélia Donatti; Terezinha Inez Estivalet Svidzinski; Márcia Edilaine Lopes Consolaro
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-08-03       Impact factor: 1.846

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.